Osteoclast derivation from mouse bone marrow

Journal of Visualized Experiments

Volumn , Issue 93, 2014, Pages

  Tevlin, Ruth ^a   McArdle, Adrian ^a   Chan, Charles K F ^a   Pluvinage, John ^a   Walmsley, Graham G ^a   Wearda, Taylor ^a   Marecic, Owen ^a   Hu, Michael S ^a   Paik, Kevin J ^a   Senarath Yapa, Kshemendra ^a   Atashroo, David A ^a   Zielins, Elizabeth R ^a   Wan, Derrick C ^a   Weissman, Irving L ^a   Longaker, Michael T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone remodeling; Bone turnover; Cellular Biology; Culture; Issue 93; Osteoclast; RANKL; Resorption assay; Skeletal homeostasis

Indexed keywords

EID: 84911360973     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/52056     Document Type: Article

References (27)

1. Sims, N. A., Martin, T. J. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKEy reports. 3, 481 (2014).
2. Kahn, A. J., Simmons, D. J. Investigation of cell lineage in bone using a chimaera of chick and quial embryonic tissue. Nature. 258, 325-327 (1975).
3. Walker, D. G. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science. 190, 784-785 (1975).
4. Burger, E. H., et al. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. The Journal of experimental medicine. 156, 1604-1614 (1982).
5. Underwood, J. C. From where comes the osteoclast. The Journal of pathology. 144, 225-226 (1984).
6. Lacey, D. L., et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nature reviews. Drug discovery. 11, 401-419 (2012).
7. Brown, J. E., Coleman, R. E. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature reviews. Clinical oncology. 9, 110-118 (2012).
8. Khosla, S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 142, 5050-5055 (2001).
9. Boyle, D. L., et al. Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss. PloS one. 9, (2014).
10. Hofbauer, L. C., Heufelder, A. E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. Journal of molecular medicine (Berlin, Germany). 79, 243-253 (2001).
11. Teramachi, J., et al. Increased IL-6 Expression in Osteoclasts is Necessary but not Sufficient for the Development of Paget's Disease of Bone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. (2013).
12. Catalfamo, D. L., et al. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. Oral diseases. 19, 303-312 (2013).
13. Schueler, J., et al. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rgamma(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PloS one. 8, (2013).
14. Xing, L., Boyce, B. F. RANKL-Based Osteoclastogenic Assays from Murine Bone Marrow Cells. Methods in molecular biology (Clifton, N.J). 1130, 307-313 (2014).
15. Weischenfeldt, J., Porse, B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH protocols. (2008).
16. Yamamoto, Y., et al. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology. 147, 3366-3374 (2006).
17. Yasuda, H., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America. 95, 3597-3602 (1998).
18. Lacey, D. L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93, 165-176 (1998).
19. Teitelbaum, S. L., Ross, F. P. Genetic regulation of osteoclast development and function. Nature reviews. Genetics. 4, 638-649 (2003).
20. Agas, D., Sabbieti, M. G., Marchetti, L. Endocrine disruptors and bone metabolism. Archives of toxicology.87, 735-751 (2013).
21. Manolagas, S. C., O'Brien, C. A., Almeida, M. The role of estrogen and androgen receptors in bone health and disease. Nature Reviews Endocrinology. 9, 699-712 (2013).
22. Martin, T. J., Udagawa, N. Hormonal regulation of osteoclast function. Trends in endocrinology and metabolism. 9, 6-12 (1998).
23. Nakamura, T., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 130, 811-823 (2007).
24. Bellido, T., et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. The Journal of clinical investigation. 95, 2886-2895 (1995).
25. Roato, I. Interaction among cells of bone, immune system, and solid tumors leads to bone metastases. Clinica., & developmental immunology. 2013, (2013).
26. Autio, K. A., Morris, M. J. Targeting bone physiology for the treatment of metastatic prostate cancer. Clinical advances in hematolog., & oncology. 11, 134-143 (2013).
27. Sottnik, J. L., Keller, E. T. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Current molecular medicine. 13, 626-639 (2013).